Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction
- Conditions
- Heterozygous Familial Hypercholesterolemia
- Interventions
- Drug: lerodalcibep
- Registration Number
- NCT04797104
- Lead Sponsor
- LIB Therapeutics LLC
- Brief Summary
This study is to assess LDL-C reductions at Week 24 and the mean of Weeks 22 and 24 with monthly Q4W (≤31 days) dosing of LIB003 300 mg administered subcutaneously (SC) compared to placebo in patients 18 years or older with Heterozygous FH on stable diet and oral LDL-C lowering drug therapy.
- Detailed Description
A randomized, double-blind, placebo-controlled, Phase 3 study of 24 weeks duration. Approximately 600 males and females aged ≥18 years with clinical or genetic heterozygous FH who fulfill the inclusion and exclusion criteria will be enrolled. Patients will be randomized in a 2:1 ratio to LIB003 (400 patients) or placebo (200 patients) administered SC Q4W (≤31 days). The study will consist of a Screening Period and a Treatment Period. The total study duration will be up to 35 weeks which includes up to an 11-week Screening Period (which may include up to a 8-week washout) and 24 weeks of study drug treatment.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 478
- Provision of written and signed informed consent prior to any study-specific procedure;
- Weight of ≥40 kg (88 lbs) and body mass index (BMI) ≥17 and ≤42 kg/m2;
- Diagnosis of definite, probable or possible HeFH based either on clinical criteria (Simon Broome register criteria or Dutch Lipid Clinics [DLC] Network Criteria) or genotyping and at the defined eligibility visit (screening or post washout/stabilization)
- LDL-C ≥70 mg/dL (if very-high risk for CVD) or ≥100 mg/dL (if high risk for CVD) and TG ≤400 mg/dL while on stable lipid lowering oral drug therapy (eg, maximally tolerated statin with or without ezetimibe); Patients unable to tolerate approved doses of a statin may take lower than approved doses and less frequently than daily as long as the dose and dosing frequency is consistent.
- Patients with documentation of inability to tolerate any statin at any dose, or history of rhabdomyolysis, and unable to tolerate any other allowed oral lipid lowering agent, and thus on no lipid lowering therapy must have an LDL-C ≥190 mg/dL (4.9 mmol/L) at the Screening Visit unless they have a documented pathogenic FH variant;
- Stable diet and other lipid lowering oral therapies besides statins and ezetimibe including bile-acid sequestrants, OM-3 compounds, fenofibrate, bezafibrate, nicotinic acid and bempedoic acid or combinations thereof for at least 4 weeks
- Patients on a PCSK9 mAb at a dose of 75 mg, 140 mg, or 150 mg Q2W must undergo a washout period of ≥4 weeks after the last dose; for those on a dose of 300 mg or 420 mg Q4W (≤31 days) the washout period is ≥8 weeks following last dose;
- Females of childbearing potential must be using a highly effective form of contraception if sexually active and have negative urine pregnancy test at the last Screening Visit
- Use of prohibited oral lipid lowering agents mipomersen or lomitapide within 6 months of screening, gemfibrozil within 6 weeks of the Screening Visit or LDL/plasma apheresis within 2 months prior to Day 1;
- Documented history of HoFH defined clinically or genetically
- History of any prior or active clinical condition or acute and/or unstable systemic disease compromising patient inclusion, at the discretion of the Investigator.
- Females of childbearing potential who are sexually active, not using or unwilling to use a highly effective form of contraception, pregnant or breastfeeding, or who have a positive urine pregnancy test at the last Screening Visit;
- Moderate to severe renal dysfunction, defined as an eGFR <30 mL/min/1.73m2
- Active liver disease or hepatic dysfunction, history of liver transplant, and/or AST or ALT >2.5 × the ULN
- Uncontrolled thyroid disease: hyperthyroidism or hypothyroidism as defined by TSH <LLN or >1.5 × ULN, respectively,
- Uncontrolled Type 1 or Type 2 DM (fasting glucose≥200 mg/dL or HbA1c of ≥9%;
- Planned cardiac surgery or revascularization;
- New York Heart Association III-IV heart failure
- Previous treatment with LIB003 or any adnectin product;
- Any other finding which, in the opinion of the Investigator, would compromise the patient's safety or participation in the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description LIB003 (lerodalcibep) lerodalcibep 300 mg (1.2 mL) SC Q4W Placebo lerodalcibep 1.2 mL SC Q4W
- Primary Outcome Measures
Name Time Method Change from baseline compared to placebo in LDL-C level 24 weeks LS mean percent change in LDL-cholesterol compared to placebo
- Secondary Outcome Measures
Name Time Method Incidence of Treatment-Emergent Adverse Events as assessed by Medical Dictionary for Regulatory Activities 24 weeks Incidence of Treatment-Emergent Adverse Events (TEAE) as assessed by Medical Dictionary for Regulatory Activities as mild, moderate or severe compared to placebo
Change in serum free PCSK9 with LIB003 compared to placebo 24 weeks Change in percent LS mean between LIB003 and placebo
Trial Locations
- Locations (7)
Department of Medicine, Hadassah University Hospital
🇮🇱Jerusalem, Israel
Rabin Medical Center, Beilinson Hospital,
🇮🇱Petah Tikva, Israel
Lipid Clinic, Oslo University Hospital
🇳🇴Oslo, Norway
Metabolic & Atherosclerosis Research Center (MARC)
🇺🇸Cincinnati, Ohio, United States
Division of Lipidology, Department of Medicine University of Cape Town
🇿🇦Cape Town, Western Province, South Africa
Carbohydrate and Lipid Metabolism Research Unit
🇿🇦Johannesburg, Gauteng, South Africa
Ege University Medical School
🇹🇷İzmir, Bornova, Turkey
Related News
Pipeline Moves: Advancement prospects plunge for Parkinson’s ...
- Prev
- 1
- Next